Table 3 Survival rate at 2 years after allo-HSCT in patients diagnosed with MDS-IB (N = 121) according to the ABO blood type and conditioning regimens
Subgroups | MDS-IB cohort (N = 121) | |||
|---|---|---|---|---|
OS (95% CI) | PFS (95% CI) | Relapse (95% CI) | NRM (95% CI) | |
Donor-recipient ABO blood type | ||||
 Compatible | 79.1% (69.1–90.6%) | 76.3% (66.1–88.1%) | 11% (4.3–21%) | 13% (6.0–23%) |
 Major/bidirectional incompatible | 58.8% (43.3–79.9%) | 51.7% (36.1–74.1%) | 23% (9.5–40%) | 25% (11–41%) |
 Minor incompatible | 73.9% (57.8–94.5%) | 70.6% (54.4–91.5%) | 13% (3.0–30%) | 17% (5.0–34%) |
 P-value | 0.039 | 0.070 | 0.237 | 0.445 |
Conditioning regimen | ||||
 RIC | 60.7% (43.8–84.0%) | 55.0% (38.6–78.5%) | 24% (9.7–43%) | 21% (7.9–37%) |
 MAC | 76.1% (67.4–85.9%) | 73.1% (64.2–83.2%) | 11% (5.3–19%) | 16% (9.2–24%) |
 P-value | 0.032 | 0.034 | 0.006 | 0.816 |